Leukemia, Myeloid, Acute

The grounding supports a clonal disease process associated with changes in myeloid precursor cells, but it does not provide a specific single cause. The literature emphasizes a genomic and molecular landscape with mutations and other molecular aberrations contributing to pathogenesis. It also notes that mechanisms of resistance to treatment are important in the disease course, but not as a primary cause.

AML involves abnormal proliferation of myeloid cells, especially myeloid blasts, in marrow and blood. The literature describes a heterogeneous genomic and molecular basis, with altered transcription factors, nucleophosmin, interleukin-3 receptor alpha subunit, and other targets studied in relation to disease biology. The bone marrow microenvironment is also implicated, with immune checkpoints, metabolic checkpoints, and signaling pathways contributing to progression, angiogenesis, metastasis, and proliferation.

The supplied grounding does not identify specific patient-level risk factors. It does indicate that genetic and molecular abnormalities are central to disease classification and biology. The bone marrow immune environment and microenvironmental alterations are described as relevant to disease severity and progression, but not as established risk factors.

The literature describes intensive chemotherapy with cytarabine plus an anthracycline as a historical backbone of treatment, along with hypomethylating agents. Allogeneic stem cell transplantation is described as an important option for eligible patients. More recent management includes targeted therapies and immunotherapy approaches such as antibodies, cellular therapies, vaccines, checkpoint blockade, and CAR T-cell or bispecific antigen-targeting strategies, with treatment guided by genetic testing and minimal residual disease assessment.